J&J takes victory lap on its Carvykti data. But how many patients will take it — and when? #ASCO23

Max Gelman

Senior Editor

Lei Lei Wu

News Reporter

CHICAGO — When Leyla Shune first heard about a leaked abstract last month describing a dramatic 74% reduction in the risk of disease progression or …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

J&J takes victory lap on its Carvykti data. But how many patients will take it — and when? #ASCO23

Max Gelman

Senior Editor

Lei Lei Wu

News Reporter

Sign up to read this article for free.

Pfizer looking to sell hospital drugs unit — reports

'Expertise is a real thing': FDA commissioner warns of political risk to agency

AstraZeneca CEO reaffirms commitment to China following executive's detention

Merck, AstraZeneca tout Phase 3 win for cancer-turned-rare disease drug

Sanofi, OpenAI, Formation Bio debut patient recruiting tool, will use in Phase 3 multiple sclerosis studies

What Will It Take to Reverse Fibrosis in Patients with Advanced MASH?

J&J takes vic­to­ry lap on its Carvyk­ti da­ta. But how many pa­tients will take it — and when? #AS­CO23

Senior Editor

News Reporter

Sign up to read this article for free.

J&J takes victory lap on its Carvykti data. But how many patients will take it — and when? #ASCO23